Press Releases - WDM Group PR Network  

Cell Therapeutics Announces Proposed Public Offering of Convertible Preferred Stock

SEATTLE, Oct. 4, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, 40,000 shares of its Series 17 Preferred Stock in an underwritten public...

Doctors Launch New Website To Improve Healthcare And Address Environmental Roots Of Disease

LOS ANGELES, Oct. 4, 2012 /PRNewswire-iReach/ -- HealthBegins, a physician-led social enterprise that improves the health of vulnerable communities with educational, technology, and consultancy services, launched the beta version of HealthBegins.org. HealthBegins.org is a free, dynamic, invite-only web platform that...

Dr. Zein Obagi Announces The Launch Of The ZO® Physician Affiliate And Revenue Sharing Programs

IRVINE, Calif., Oct. 4, 2012 /PRNewswire/ -- ZO Skin Health, Inc., is pleased to announce the launch of the ZO® Physician Affiliate and Revenue Sharing Programs specifically tailored to support a thriving physician practice. The ZO® Affiliate Program is an...

Lorus Therapeutics to Present at BioContact 2012 in Quebec City

Lorus Therapeutics Inc.
Grace Tse
416-798-1200 ext. 380
ir@lorusthera.com
www.lorusthera.com

Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy

Sarepta Investor and Media Contact:
Erin Cox
425.354.5140
Email Contact

Sarepta Therapeutics Receives Notice From Department of Defense for Termination of Ebola Therapeutic Program

Sarepta Investor and Media Contact:
Erin Cox
425.354.5140
Email Contact

Stemnion Selects KineMatik ELN as Their Enterprise Research Data Management Platform

Michael Price
630-778-6900
Email Contact

Charles Hensley, Ph.D., and Itonis Pharmaceuticals Announce Anti-HIV Compound Targeting the Viral Entry Step

Contact:
Michael Biddick
Email Contact
(949) 529-1588

Med BioGene Provides Update

Med BioGene Inc.
Erinn B. Broshko
Executive Chairman
(800) 641-3593
ebroshko@medbiogene.com
www.medbiogene.com

Lpath Begins iSONEP Dosing in Nexus Phase 2 Study

Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
Email Contact

Lpath Investor Relations
Liolios Group, Inc.
(949) 574-3860
Email Contact
Ron Both: Email Contact
Geoffrey Plank: Email Contact

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | ...


Featured Articles + MORE Featured Articles >>